Thought Leadership | Multi-cancer early detection | Exact Sciences
United States
Choose your country or region:
Cancerguard™ / Thought Leadership

We are growing thought leadership for the MCED field

Read scientific publications, watch presentations and talks, and learn about new initiatives here.

Highlights you don’t want to miss

AACR 2024 poster

Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort


Poster – 2024 American Association for Cancer Research Annual Meeting
Shifting the Paradigm in Cancer Screening: Multi-cancer Early Detection Testing

Shifting the Paradigm in Cancer Screening: Multi-Cancer Early Detection Testing


ESMO 2023 Industry Satellite Symposium
WATCH NOW

See our advancements presented at the European Society of Medical Oncology (ESMO) Congress 2023

Publications + abstracts

AACR 2024 poster

Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort


Poster – 2024 American Association for Cancer Research Annual Meeting
Download the poster

See our advancements presented at the European Society of Medical Oncology (ESMO) Congress 2023

Read press release
Download poster

Long-term clinical outcomes of cancer diagnosed following detection by a blood-based MCED test


Poster - American Society of Clinical Oncology Annual Meeting 2023
Download the poster

Evaluating the diagnostic burden of tumor localization strategies for multi-cancer early detection tests


Poster - 2023 American Association for Cancer Research Annual Meeting
Download the poster

Improved sensitivity of multi-analyte early detection test based on mutation, methylation, aneuploidy, and protein biomarkers


Poster - American Association for Cancer Research Special Conference 2022
Download the poster

Multi-cancer early detection through evaluation of aneuploidy, methylation, mutation, and protein biomarkers in plasma


Abstract - ESMO Congress 2022

 

Download the poster

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention


Research article on DETECT-A study in Science, April 2020
Read the article

Multi-cancer early detection through multiple analyte testing


Overview Slide Set for Scientific Exchange
Download slides
SEE MORE

Talks + podcasts

Long-term clinical outcomes of cancers diagnosed following detection by a blood-based MCED test


American Society of Clinical Oncology Annual Meeting 2023
Watch

Improved sensitivity of a multi-analyte early detection test based on mutation, methylation, aneuploidy, & protein biomarkers


American Association for Cancer Research Special Conference 2022
Watch

Imaging-based localization for MCED tests yields lower diagnostic burden


American Association for Cancer Research Annual Meeting 2023
Watch

Multi-cancer early detection: framing the future of cancer screening


Are new cancer screening tools around the corner to complement the existing standards of care? And how could we detect more cancers earlier?
Listen

Addressing screening limitations through multi-cancer early detection tests


Could MCED tests help address some of the most common limitations associated with current cancer screening methods, like a lack of adherence and access?
Listen
lab

Shifting the Paradigm for Early Cancer Detection: A Multi-biomarker Class Approach to MCED Testing


2023 American Society for Clinical Oncology Annual Meeting Industry Expert Theater presentation recording
WATCH NOW

Exact Sciences' MCED testing content page on ReachMD.com

 

Content highlighting MCED testing posters presented at recent conferences and insights about the potential impact MCED testing may have on cancer screening

 

Watch Now

ACCC Webinar: MCED 101


Discussion with thought leader Chetan Bettegowda, MD, PhD, Professor of Neurosurgery, The Johns Hopkins University School of Medicine
Watch THE WEBINAR

Becker’s Hospital Review Podcast: Multi-Cancer Early Detection


Conversation with Tom Beer, MD, FACP, Chief Medical Officer and Vice President, Multi-Cancer Early Detection at Exact Sciences
Listen Now
Shifting the Paradigm in Cancer Screening: Multi-cancer Early Detection Testing

Shifting the Paradigm in Cancer Screening: Multi-Cancer Early Detection Testing


ESMO 2023 Industry Satellite Symposium
WATCH NOW
SEE MORE

Organizations + initiatives

Cancer Moonshot


The White House Fact Sheet: President Biden Reignites Cancer Moonshot to End Cancer as We Know It
Read the statement

Congress bill H.R. 2407


Proposed 2023 legislation to support MCED testing and create a pathway for Medicare access to these tests
Learn more

MCED Consortium


An independent, nonprofit, US/UK public-private consortium that aims to evaluate emerging data from MCED studies and establish standards in MCED technology
Visit site

BLOODPAC


A nonprofit consortium focused on accelerating the development, validation and accessibility of liquid biopsy assays for cancer care. BLOODPAC works to enable information sharing between key stakeholders in public, industry, nonprofit, academia and regulatory agencies, with the ultimate goal of improving patient care and outcomes.
Visit site

American Cancer Society – Cancer Action Network (ACS CAN)


Advocates for evidence-based public policies to reduce the cancer burden for everyone. They believe everyone should have a fair and just opportunity to prevent, detect, treat, and survive cancer.
Visit site

National Minority Quality Forum


Founded to address the critical need for strengthening national and local efforts to use evidence-based, data-driven initiatives to guide programs to eliminate the disproportionate burden of premature death and preventable illness for racial and ethnic minorities and other special populations
Visit site

Prevent Cancer Foundation


Empowering people to stay ahead of cancer through prevention and early detection
Visit site
SEE MORE

The Cancerguard™ test is under development. The features above describe current development goals. It has not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.